Suchergebnisse - (Subject:"Siltuximab")

PubPharm (226)

71

Adult Langerhans cell histiocytosis of skull in a patient with synchronous papillary thyroid carcinoma and Castleman disease

enthalten in: BMJ case reports | 2021

von Kim, I. | Lee, K.

72

Unicentric Castlemans disease. Symptoms, diagnostics and therapy

enthalten in: Vnitrni lekarstvi | 2021

von Adam, Z. | Řehák, Z. | Adamová, Z. | +8

73

in: Gaceta Médica de México | 2021

von Roberto Ovilla-Martínez | Pamela E. Báez-Islas | Xóchitl Cota-Rangel | +1

74

Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19

in: Current Medicine Research and Practice | 2021

von I Jerlin Michelle | S A Shevaani | Kiran Kumar Rathinam | +3

75

Potential Immunological Treatments in COVID-19 Patients

in: Düzce Tıp Fakültesi Dergisi | 2021

von Muhammet Mesut Nezir Engin | Öner Özdemir

76

TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy

in: Case Reports in Oncology | 2021

von Corinne Williams | Alexis Phillips | Vikram Aggarwal | +3

77

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease

in: The Korean Journal of Internal Medicine | 2021

von Gi-June Min | Young-Woo Jeon | Sung-Soo Park | +14

78

Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome

enthalten in: International journal of medical sciences | 2021

von Du, P. | Geng, J. | Wang, F. | +3

79

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

enthalten in: American journal of hematology | 2020

von Fajgenbaum, D. | Wu, D. | Goodman, A. | +21

80

Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19

enthalten in: Infectious diseases and therapy | 2020

von Meletiadis, J. | Tsiodras, S. | Tsirigotis, P.